Holen Sie sich die Stockscreener-App
113.80
77.44%
49.69
Schlusskurs vom Vortag:
$64.11
Offen:
$114.14
24-Stunden-Volumen:
25.26M
Relative Volume:
17.97
Marktkapitalisierung:
$6.58B
Einnahmen:
$76.81M
Nettoeinkommen (Verlust:
$-162.42M
KGV:
-38.06
EPS:
-2.99
Netto-Cashflow:
$-122.49M
1W Leistung:
+66.07%
1M Leistung:
+68.03%
6M Leistung:
+59.59%
1J Leistung:
+78.45%
1-Tages-Spanne:
$113.72
$114.26
1-Wochen-Bereich:
$63.15
$114.26
52-Wochen-Spanne:
$47.86
$114.26
Arcellx Inc Stock (ACLX) Company Profile
Firmenname
Arcellx Inc
Sektor
Branche
Telefon
240-327-0603
Adresse
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
113.78 | 3.71B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.94 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.97 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.73 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.66 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
367.25 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-22 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-07 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-04 | Bestätigt | Needham | Buy |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-10-30 | Eingeleitet | TD Cowen | Outperform |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-05-18 | Eingeleitet | Truist | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-14 | Eingeleitet | Stifel | Buy |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-13 | Fortgesetzt | BofA Securities | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-27 | Eingeleitet | Needham | Buy |
| 2022-07-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-03-01 | Eingeleitet | BofA Securities | Buy |
| 2022-03-01 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Gilead Sciences Expands Oncology Portfolio with Arcellx Acquisition - GuruFocus
Arcellx Gains Spotlight with Innovative Presentation and Stock Sale Update - StocksToTrade
Midday Fly By: Trump ups worldwide tariff to 15%, Gilead buying Arcellx - TipRanks
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Arcellx Stock (ACLX) Rockets on a Massive Deal with Gilead Sciences (GILD) - TipRanks
Gilead acquires CAR-T specialist Arcellx for $7.8bn - Pharmaceutical Technology
ACLX Downgraded by Needham: New Rating Update | ACLX Stock News - GuruFocus
What Gilead Is Getting Through The Acquisition Of Arcellx - Seeking Alpha
Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders - Financial Times
Gilead to acquire CAR-T biotech Arcellx for $7.8bn - EMJ | Elevating the quality of healthcare globally
Gilead buys Arcellx before it’s over the finish line | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion - marketscreener.com
Gilead to buy Arcellx in $7.8bn deal to advance multiple myeloma treatment - BioXconomy
Gilead Sciences Enters $7.8 Billion Definitive Agreement to Acquire Arcellx - Pharmaceutical Executive
Arcellx Surges as Gilead’s $7.8B Offer Locks In a 68% Premium - Investing.com
Novo Nordisk, Lilly, Arcellx, American Airlines, Strategy, Domino’s, and More Movers - Barron's
Gilead to buy Arcellx for $7.8B, gaining full control of anito-cel - FirstWord Pharma
Why Did Arcellx (ACLX) Stock Surge 70%? $7.8B Buyout Deal - Tokenist
Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J - Investor's Business Daily
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - WKZO
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Gilead to buy biotech Arcellx in deal worth up to $7.8 billion - MSN
Arcellx Stock Surges on Promising Cancer Treatment News - StocksToTrade
Why is Arcellx stock up 80% today? Gilead’s $7.8B answer - Invezz
Gilead Sciences To Acquire Arcellx In $7.8 Billion Deal To Strengthen Cell Therapy Portfolio - Pulse 2.0
Arcellx surges after Gilead agrees to acquire the CAR-T biotech in a deal worth up to $7.8B - Quiver Quantitative
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy - BioPharma Dive
Stock Movers: Gilead, Novo Nordisk, Domino's - Bloomberg.com
Novo’s next-gen obesity drug stumbles in Lilly comparison study - statnews.com
Truist cuts Arcellx stock rating on Gilead acquisition deal By Investing.com - Investing.com India
Spider silk strong enough to tow a car is headed for mass production in Vietnam - Stock Titan
Gilead to Buy US Biotech Arcellx for Up to $7.8 Billion - Bloomberg.com
Sector Update: Health Care Stocks Mixed Premarket Monday - marketscreener.com
Gilead Sciences to buy Arcellx to maximize long-term potential of anito-cel - MLex
Morning Movers: Arcellx skyrockets following pact to be acquired - TipRanks
Gilead Sciences Acquires Arcellx, for $7.8 Billion - FinSMEs
Gilead Sciences to snap up Arcellx in near $8bn deal - Sharecast.com
Why Arcellx Stock Is Dropping Despite Buyout Deal - TipRanks
Gilead to buy Arcellx for $7.8B to expand cancer therapy pipeline - Latest news from Azerbaijan
Truist cuts Arcellx stock rating on Gilead acquisition deal - Investing.com
Gilead Sciences Acquires Arcellx - Contract Pharma
Gilead Sciences to buy Arcellx in deal worth up to $7.8B - MSN
This Biotech Stock Is Surging 78%. Gilead Sciences Has Agreed to Buy It. - Barron's
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition - BioSpace
Gilead Snaps Up Arcellx in $7.8B Cancer Drug Deal - RagingBull
Arcellx stock soars 78% as Gilead agrees to $7.8B acquisition - Investing.com Australia
Arcellx stock soars 78% as Gilead agrees to $7.8B acquisition By Investing.com - Investing.com South Africa
US Gilead Sciences acquires cancer drug developer Arcellx for $7.8B - Anadolu Ajansı
Gilead buys cell therapy partner Arcellx for up to $7.8bn - pharmaphorum
ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders - The National Law Review
Gilead Sciences (GILD) Announces Strategic Merger with Arcellx - GuruFocus
Finanzdaten der Arcellx Inc-Aktie (ACLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arcellx Inc-Aktie (ACLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Jan 03 '26 |
Option Exercise |
0.00 |
15,340 |
0 |
44,302 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Feb 19 '26 |
Sale |
68.29 |
8,384 |
572,568 |
45,157 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Jan 02 '26 |
Option Exercise |
0.00 |
20,496 |
0 |
28,962 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Feb 17 '26 |
Sale |
69.51 |
11,291 |
784,783 |
53,541 |
0.58%
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):